[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"tumor-brain\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:tumor-brain":28},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,5,0,[8,42,74,109,129],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":30,"lastUpdatePostDateStruct":31,"startDateStruct":34,"completionDateStruct":36,"leadSponsor":38,"locationsCount":41},"100445904","wbsi-guided-personalized-delivery-of-ttfields-100445904",false,"NCT05086497","WBSI Guided Personalized Delivery of TTFields","Whole-Brain Spectroscopy Guided Personalized Mapping of Transducer Arrays for Glioblastoma Patients Receiving Tumor Treating Fields","Inclusion Criteria:\n\n* Adult population ≥ 22 years\n* Histologically confirmed diagnosis of GBM or molecular GBM according to c-IMPACT NOW criteria\n* Have undergone maximal safe surgical resection followed by either standard full course radiation of 6000 cGy in 6 weeks or a hypofractionated course of 4000 cGy in 3 weeks\n* 3 Harboring any genotype profiles (MGMT promoter methylation or unmethylation and\u002For isocitrate dehydrogenase (IDH) mutant or IDH wild-type)\n* Possessing adequate hematological, hepatic and renal functions\n* Willingness to receive TTFields\n\nExclusion Criteria:\n\n* Presence of infra-tentorial GBM\n* Pregnancy\n* Significant co-morbidities at baseline which would prevent maintenance TMZ treatment\n* Active implanted medical device, a skull defect (such as missing bone with no replacement) or bullet fragments. Examples of active electronic devices include deep brain stimulators, spinal cord stimulators, vagus nerve stimulators,pacemakers, defibrillators and programmable shunts. , other implanted electronic devices in the brain.\n* Sensitivity to conductive hydrogels like the gel used on electrocardiogram (ECG) stickers or transcutaneous electrical nerve stimulation (TENS) electrodes.\n* Presence of significant hemorrhage in and around the tumor bed that may potentially degrade the image quality.","ALL","22 Years",{"count":19,"type":20},155,"ESTIMATED","INTERVENTIONAL",[23],"NA","This research study is for Glioblastoma (GBM) patients who will be beginning Optune as part of their clinical care, which is a novel treatment that utilizes - tumor treating fields (TTFields), (aka, electrical therapy), which has shown to improve overall survival in large multi-center trials. As a part of this study, participants will either receive Optune with \"standard array mapping\" (based on regular contrast enhanced MRI) or an \"alternative (more precise) array mapping\" based on sophisticated state of the art MRI techniques including \"whole brain spectroscopy\". Whole brain MRI spectroscopy provides additional metabolic information to map out the full extent of tumor spreading within the brain (far beyond from what is seen on regular MRI), by identifying certain metabolites that are present in cancer cells versus healthy tissue. This study is being performed to show whether alternative array mapping improves treatment outcomes, as opposed to the standard array mapping, by maximizing delivery of TTFields dose, thereby achieving more effective tumor cell killing, decreasing the rate of local recurrence, and improving the overall survival as well as quality of life measures.",[26,27,28],"GBM","Glioma Glioblastoma Multiforme","Tumor, Brain","RECRUITING","2026-03-09",{"date":32,"type":33},"2026-03-11","ACTUAL",{"date":35,"type":33},"2023-01-15",{"date":37,"type":20},"2026-06-30",{"name":39,"class":40},"Abramson Cancer Center at Penn Medicine","OTHER",2,{"id":43,"slug":44,"hasResults":11,"nctId":45,"briefTitle":46,"officialTitle":4,"acronym":4,"eligibilityCriteria":47,"healthyVolunteers":11,"sex":16,"minAge":4,"maxAge":4,"enrollmentInfo":4,"targetDuration":4,"studyType":48,"phases":4,"briefSummary":49,"conditions":50,"keywords":4,"overallStatus":67,"whyStopped":4,"lastUpdateSubmitDate":68,"lastUpdatePostDateStruct":69,"startDateStruct":4,"completionDateStruct":4,"leadSponsor":71,"locationsCount":4},"100514124","expanded-access-to-immunomodulatory-avm0703-for-solid-tumor-and-blood-cancer-patients-100514124","NCT05974410","Expanded Access to Immunomodulatory AVM0703 for Solid Tumor and Blood Cancer Patients","Inclusion Criteria:\n\n\\-\n\nExclusion Criteria:\n\n\\-","EXPANDED_ACCESS","AVM Biotechnology, Inc., provides immunomodulatory AVM0703 to solid tumor and blood cancer patients upon request by a US licensed MD or DO. As of July 2024, 37 patients have been treated through this FDA-EAP including patients diagnosed with relapsed or recurring glioblastoma, inoperable\u002Fchemotherapy ineligible CNS Squamous Cell Carcinoma, metastatic Breast Cancer, ovarian cancer, gastric cancer, Hodgkin's Lymphoma, Mixed Phenotype Acute Myelogenous Leukemia, colon cancer, B-ALL, Malignant Myxoid Spindle Cell Neoplasm, non-small cell lung cancer, DLBCL with CNS involvement, metastatic prostate cancer, Anaplastic T-cell Non-Hodgkin's Lymphoma and metastatic pancreatic cancer. Drug-related side-effects are predominantly grade 1 and include itching during the infusion and about 1 week of low grade insomnia.",[51,52,53,54,55,56,57,58,59,60,61,62,63,28,64,65,66],"Glioblastoma","Squamous Cell Carcinoma","Hodgkin Lymphoma","Non-hodgkin Lymphoma","Breast Cancer","Prostate Cancer","Gastric Cancer","Ovarian Cancer","Acute Leukemia","Pancreatic Cancer","Spindle Cell Sarcoma","Cancer","Tumor, Solid","Esophageal Andeocarcinoma","Mixed Phenotype AML","Desmoplastic Round Cell Sarcoma","AVAILABLE","2025-09-29",{"date":70,"type":33},"2025-10-02",{"name":72,"class":73},"AVM Biotechnology Inc","INDUSTRY",{"id":75,"slug":76,"hasResults":11,"nctId":77,"briefTitle":78,"officialTitle":79,"acronym":80,"eligibilityCriteria":81,"healthyVolunteers":11,"sex":16,"minAge":82,"maxAge":83,"enrollmentInfo":84,"targetDuration":4,"studyType":21,"phases":86,"briefSummary":87,"conditions":88,"keywords":92,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":98,"lastUpdatePostDateStruct":99,"startDateStruct":101,"completionDateStruct":103,"leadSponsor":105,"locationsCount":108},"100475957","intraoperative-brain-shift-calculation-study-100475957","NCT05477680","Intraoperative Brain Shift Calculation Study","Intraoperative Brain Shift Calculation Study: a Prospective, Single Arm Clinical Trial","BRASH","Inclusion Criteria:\n\n* all intracranial tumors\n* cavernomas\n* arteriovenous malformations\n* spontaneous (non-traumatic) intracerebral hemorrhages\n* traumatic intracerebral hemorrhages\n* supratentorial localization\n* newly diagnosed\n* age 18-100 years\n* stable hemodynamics\n* error of patient registration in neuronavigation no more than 2 mm\n\nExclusion Criteria:\n\n* rapid cerebral dislocation","18 Years","100 Years",{"count":85,"type":20},100,[23],"The purpose of the study is to calculate magnitude, type of intraoperative brain shift and assess possibility of it's prediction.",[28,89,90,91],"Cavernoma","Arteriovenous Malformations","Intracerebral Hematoma",[93,94,95,96,97],"brain shift","tumor","cavernoma","arteriovenous malformation","intracerebral hematoma","2025-05-13",{"date":100,"type":33},"2025-05-16",{"date":102,"type":33},"2022-09-01",{"date":104,"type":20},"2027-08-31",{"name":106,"class":107},"Sklifosovsky Institute of Emergency Care","OTHER_GOV",1,{"id":110,"slug":111,"hasResults":11,"nctId":112,"briefTitle":113,"officialTitle":114,"acronym":115,"eligibilityCriteria":116,"healthyVolunteers":11,"sex":16,"minAge":82,"maxAge":83,"enrollmentInfo":117,"targetDuration":4,"studyType":21,"phases":118,"briefSummary":119,"conditions":120,"keywords":121,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":98,"lastUpdatePostDateStruct":125,"startDateStruct":126,"completionDateStruct":127,"leadSponsor":128,"locationsCount":108},"100476462","sonography-guided-resection-of-brain-mass-lesions-100476462","NCT05484245","Sonography-guided Resection of Brain Mass Lesions","Sonography-guided Resection of Brain Mass Lesions: a Prospective, Single Arm Clinical Trial","SOMALI","Inclusion Criteria:\n\n* all intracranial tumors\n* cavernomas\n* arteriovenous malformations\n* spontaneous (non-traumatic) intracerebral hemorrhages\n* traumatic intracerebral hemorrhages\n* supratentorial localization\n* newly diagnosed\n* age 18-100 years\n* stable hemodynamics\n\nExclusion Criteria:\n\n* rapid cerebral dislocation\n* previously performed brain radiotherapy",{"count":85,"type":20},[23],"Objective of the study is to determine possibilities of intraoperative sonography in detecting of various brain mass lesions, assessing extent of their resection and define indications to use ultrasound-guided needle or ultrasound wire-guided port.",[28,90,89,91],[122,123,124,95,96,97],"intraoperative sonography","intraoperative ultrasound","brain tumor",{"date":100,"type":33},{"date":102,"type":33},{"date":104,"type":20},{"name":106,"class":107},{"id":130,"slug":131,"hasResults":11,"nctId":132,"briefTitle":133,"officialTitle":134,"acronym":135,"eligibilityCriteria":136,"healthyVolunteers":11,"sex":16,"minAge":137,"maxAge":138,"enrollmentInfo":139,"targetDuration":4,"studyType":21,"phases":141,"briefSummary":142,"conditions":143,"keywords":152,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":154,"lastUpdatePostDateStruct":155,"startDateStruct":157,"completionDateStruct":159,"leadSponsor":161,"locationsCount":108},"100498995","music-therapy-in-complex-specialist-neurorehabilitation-100498995","NCT05777499","MUSic Therapy In Complex Specialist Neurorehabilitation","Pilot Study to Evaluate MUSic Therapy in Complex Specialist Neurorehabilitation","MUSICS","Inclusion Criteria:\n\n* Age 16 years or above.\n* Clinical diagnosis of a neurological injury involving the brain, spinal cord, and\u002For peripheral nerves, sustained during the current hospital admission.\n* Participant has complex rehabilitation needs warranting admission to a specialist neurorehabilitation unit.\n* Willing and able to provide written informed consent. If the participant is unable to demonstrate sufficient mental capacity to provide informed consent, the multidisciplinary team will liaise with the participant to identify a suitable consultee to determine suitability to participate in the study in their best interests.\n\nExclusion Criteria:\n\n* Participant is medically unstable or excessively drowsy, and is unexpected to be able to tolerate an intensive rehabilitation program.\n* Participant is expected to be discharged from hospital before 10 weeks.\n* Concurrent and\u002For recent involvement in other research that is likely to interfere with the intervention within the last 3 months of study enrolment.","16 Years","80 Years",{"count":140,"type":20},75,[23],"Aim: Investigate whether patients undergoing specialist rehabilitation after complex neurological injury show different functional outcomes if music therapy is included in their rehabilitation program compared to usual care.\n\nBackground: Patients with complex needs following a brain, spinal cord, and\u002For peripheral nerve injury often require a period of specialist neurorehabilitation. This involves multiple therapy disciplines, led by a Consultant in Rehabilitation Medicine, Neurology, or Neuropsychiatry. Although music therapy is suggested to enhance neuroplasticity and recovery in patients with brain injury, it is not routinely commissioned in clinical care due to a lack of supportive evidence.\n\nHypothesis: Patients undergoing music therapy in addition to complex specialist rehabilitation show better functional outcomes compared to usual care.\n\nNumber of participants: 75, aged 16-80 years. Methods: Patients undergo baseline assessments and are randomised to MUSIC or CONTROL Therapy. Both arms receive 1-3 additional therapy sessions per week, matched for duration and number, total 15 hours. After approximately 10-weeks intervention, assessments are repeated. All participants then have access to music therapy until they are discharged from Neurorehabilitation Unit (NRU), with additional qualitative data collection using semi-structured interviews, field notes, staff reports, staff stress surveys, and broader ecological observations.\n\nDuration for Participants: From consent to discharge from NRU. Primary Outcome: Change in Functional Independence Measure+Functional Assessment Measure (FIM+FAM), Northwick Park Dependency Scale (NWPDS), and Barthel Activities of Daily Living pre and post 15 hours intervention.\n\nSecondary Outcome: Change in quality of life (Flourishing Scale), psychological distress (Hospital Anxiety and Depression Scale, Depression Intensity Scale Circles), social interaction (Sickness Impact Profile Social Interaction Subscale), well-being (WHO Well-Being Index), and communication (Communication Outcomes After Stroke Scale), pre and post 15 hours intervention. Mean difference in well-being (WHO Well-Being Index) throughout the intervention period between music therapy and control therapy groups. Mean difference in post-intervention pain and mood visual analogue scores between music therapy and control therapy groups.",[144,145,146,28,147,148,149,150,151],"Stroke","Subarachnoid Hemorrhage","Traumatic Brain Injury","Autoimmune Diseases","Meningitis\u002FEncephalitis","Acquired Brain Injury","Spinal Cord Injuries","Peripheral Nervous System Diseases",[153],"Neurological injury","2024-10-21",{"date":156,"type":33},"2024-10-23",{"date":158,"type":33},"2023-06-05",{"date":160,"type":20},"2025-10",{"name":162,"class":40},"University College, London"]